Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations The results for this additional indication for BKT-140/BL-8040 will be presented at the Society of Hematologic Oncology (SOHO) Annual Meeting. BKT-140/BL-8040 is also undergoing Phase 2 study in AML, with the final results expected in early 2015. It is also in a [...]

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment The results from the phase 1 trial expected by end of 2014 or early 2015. BKT-140/BL-8040 is also in the midst of a Phase 2 trial for AML, with results expected in early 2015. Read More

Go to Top